Personalized neoantigen-targeting cancer vaccines showed safety and immune activity in high-grade epithelial ovarian cancer patients, with 75% of recurrent patients vaccinated.
Immunotherapy and Immune Responses
Moving in Nature Medicine.
- Moved, week to 23 Oct 2026
- 1
- Papers in 60 days
- 65
Add Immunotherapy and Immune Responses as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Latest in Immunotherapy and Immune Responses
Newest first · last 60 days
TCR T cells targeting IgA- and IgG-expressing multiple myeloma eliminate HLA-A∗02:01+ MM cells in vitro and in vivo, showing promise for therapy in about 40% of European descent patients.
- Open access
- 1 cites
Personalized neoantigen-targeting cancer vaccines showed safety and immune activity in high-grade epithelial ovarian cancer patients, with 75% of recurrent patients vaccinated.
Cancers evade T cell detection by avoiding presentation of p53 neoantigens through multiple mechanisms, including mutation localization and HLA allele loss.
TLR9-activated B cells enhance CD8+ T-cell antitumor activity via a CD2-dependent costimulation axis in cancer therapy.
- Open access
Inhalable BEAT exosomes co-displaying PD-1 and FZD8 activate T cells and produce robust antitumor effects in ICI-resistant melanoma mouse models.
- Open access
- 4 cites
Metastasis-associated migrasomes are enriched in tumor antigens and promote CD8+ T cell responses that constrain metastatic progression.
- Open access
CAR-T cell therapy and cancer nanovaccines are emerging as powerful, potentially complementary immunotherapy strategies with distinct strengths and limitations across studies.
- Open access
Immune checkpoint inhibitor-based combinations are now the standard first-line systemic therapy for advanced hepatocellular carcinoma, showing improved survival and response rates.
- Open access
Monocyte-derived galectin-1(hi) cells are essential for the formation and maintenance of lung CD8+ tissue-resident memory T cells after influenza infection.
- 1 cites
Antibody-lectin chimeras (AbLecs) outperform most existing therapies by reducing tumor burden in a humanized mouse model, demonstrating potent glyco-immune checkpoint blockade.
- Open access
- 32 cites
Intestinal epithelial cell presentation of cytosol-delivered bacterial antigens programs robust mucosal CD4 T cell responses and epithelial-resident memory in mice.
- Open access
- 1 cites
Synthetic pH-responsive membranolytic peptide aMP C16-CA50 induces immunogenic cell death in tumor cells, enhancing immune checkpoint blockade therapy in mice.
Fifth-generation GD2-CAR T cells secreting anti-PD-L1 scFv show superior cytotoxicity against GD2-low retinoblastoma cells at low effector-to-target ratios.
- Open access
A super enhancer between HLA-DR and -DQ genes regulates their expression through microdomains, with specific regions controlling HLA-DQA1 and HLA-DRB1 levels.
- Open access
Add Immunotherapy and Immune Responses as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3